VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s (Q34613164)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s |
scientific article |
Statements
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study (English)
Paul G Richardson
Maria-Victoria Mateos
Michel Delforge
Nuriet K Khuageva
Ofer Shpilberg
Maria T Petrucci
Rik Schots
William Deraedt
Andrew Cakana
Helgi van de Velde
Rudolf Schlag
Martin Kropff
Julia Alexeeva
26 October 2009